|"Medtronic Inc.’s CoreValve is photographed at an American College of Cardiology Conference in Washington, on Saturday. A new study gives a big boost to fixing a bad aortic valve, the heart's main gate, without open-heart surgery."|
Precision Medicine will need to get out of the pharma silo that is based on symptoms
Welcome to the digital era of biology (and to this modest blog I started in early 2005).
To cure many diseases, like cancer or cystic fibrosis, we will need to target genes (mutations, for ex.), not organs! I am convinced that the future of replacement medicine (organ transplant) is genomics (the science of the human genome). In 10 years we will be replacing (modifying) genes; not organs!
Anticipating the $100 genome era and the P4™ medicine revolution. P4 Medicine (Predictive, Personalized, Preventive, & Participatory): Catalyzing a Revolution from Reactive to Proactive Medicine.
After low-cost airlines (Ryanair, Easyjet ...) comes "low-cost" participatory medicine. Some of my readers have recently christened this long-lasting, clumsy attempt at e-writing of mine "THE LOW-COSTE INNOVATION BLOG". I am an early adopter of scientific MOOCs. My name's Catherine Coste. I've earned myself four MIT digital diplomas: 7.00x, 7.28x1, 7.28.x2 and 7QBWx. Instructor of 7.00x: Eric Lander PhD.
Upcoming books: Doomsdare, a medical thriller (action taking place in Beijing) Fall 2016; Jesus CRISPR Superstar, a sci-fi -- French title: La Passion du CRISPR (2017). Special thanks to Prof. Emmanuel Lincot, lawyer David Kilgour and Isabelle Provost for their help.
I love Genomics. Would you rather donate your data, or... your vital organs?
Audio files on this blog are Windows files ; if you have a Mac, you might want to use VLC (http://www.videolan.org) to read them.
Concernant les fichiers son ou audio (audio files) sur ce blog : ce sont des fichiers Windows ; pour les lire sur Mac, il faut les ouvrir avec VLC (http://www.videolan.org).
"Nonsurgical Fix Could Replace Open-Heart Surgery, Study Suggests"
The results were reported Saturday at an American College of Cardiology conference in Washington and prompted some doctors to predict that in the near future, far fewer people will be having the traditional operation.
'It's going to be very hard to tell a patient that if they need an aortic valve, surgery is going to be their best option,' said one of the conference leaders, Dr. Prediman K. Shah of Cedars Sinai Heart Institute in Los Angeles.
Several hundred thousand Americans have a bad aortic valve, which can stiffen and narrow with age, keeping blood from passing through as it should. Until a few years ago, the only solution was a major operation to open the chest, cut out the bad valve and sew in a new one.
Earlier this year, (...) Medtronic Inc.'s CoreValve was approved for treating people at too high risk to have surgery. The new study tested it in nearly 800 people less sick — eligible for the operation but still with elevated risks.
One year after treatment, 19 percent of the surgery patients but only 14 percent of those given a CoreValve had died.
'It's a great leap forward' for fixing valves through blood vessels, said Dr. David Kandzari of Piedmont Heart Institute in Atlanta.
The study was paid for by Medtronic, and many study leaders consult for Medtronic, Edwards or other heart device makers. Results also were published online by the New England Journal of Medicine."